Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Recommendation of “Moderate Buy” by Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $67.50.

Several equities research analysts have commented on the company. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Canaccord Genuity Group upped their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, August 14th. HC Wainwright boosted their target price on Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 125,000 shares of company stock worth $6,204,250 over the last 90 days. Corporate insiders own 16.49% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Opaleye Management Inc. increased its stake in shares of Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after purchasing an additional 7,930 shares in the last quarter. EcoR1 Capital LLC raised its position in shares of Eton Pharmaceuticals by 7.0% in the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after buying an additional 141,394 shares during the period. BlackRock Inc. purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth about $68,629,000. Vanguard Group Inc. raised its stake in shares of Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after acquiring an additional 31,942 shares during the period. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals during the second quarter valued at approximately $42,569,426. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $59.78 on Monday. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 157.32 and a beta of 0.86. Eton Pharmaceuticals has a 52 week low of $14.27 and a 52 week high of $66.37. The business’s 50-day moving average price is $45.17 and its 200 day moving average price is $32.02. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.24. The firm had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. As a group, sell-side analysts anticipate that Eton Pharmaceuticals will post 1.13 earnings per share for the current year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.